Abstract: There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an 18F-labeled arachidonic acid to a subject in need thereof, obtaining a positron emission tomography (PET) scan of the subject, and determine the extent of neuroinflammation from the PET scan. There are provided, inter alia, methods of synthesis of reagents useful for the production of an 18F-labeled arachidonic acid.

Abstract: The present invention is directed to the targeting of drugs, peptides, and proteins to the brain. Liposomes containing the compound to be delivered are coupled to antibody binding fragments which bind to receptors on the vascular endothelium of the blood-brain barrier. The targeted receptors include transferrin receptor, insulin receptor, IGF-I and IGF-II receptors, among others. Also provided are pharmaceutical compositions and methods for administering the drugs to a subject in need by means of the receptor-targeted immunoliposomes.

Abstract: An improved method of cholinomimetic therapy for cognitive impairments associated with aging and Alzheimer's disease comprising treating a patient with an effective amount of phenserine or a pharmaceutically acceptable salt and derivatives.

Abstract: The present invention relates to substituted phenylcarbamate or naphthylcarbamate tricyclic compounds which provide highly potent and selective cholinergic agonist and blocking activity and their use as pharmaceutical agents. The invention further relates to improvements in therapy relative to cholinergic diseases such as glacuoma, Myasthenia Gravis, Alzheimer's disease and to improvements in therapy and organophosphate poisoning. The invention further provides for a selective acetylcholinesterase and butyrylcholinesterase agents and a method for inhibiting these esterases.

Abstract: Highly potent analogs of (-)-physostigmine are provided which are potent inhibitors of acetylcholinesterase and butyrylcholinesterase. These compounds are useful in treatment of glaucoma, Alzheimer's disease, myasthenia gravis, and organophosphate poisoning.

Abstract: Tertiary butyl esters of anticancer drugs are provided which have the following formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of H, F, Cl, Br, and I and R.sub.2 can also be NH.sub.2 ;R.sub.3, R.sub.4, and R.sub.5 are the same or different and are selected from the group consisting of H, F, Cl, Br, I, and C.sub.1 -C.sub.3 alkyl; wherein alkyl may be substituted with F, Cl, Br, or I, with the proviso that at least two of R.sub.3, R.sub.4, and R.sub.5 are alkyl or substituted alkyl; andn=0-4.The compounds of the present invention can be used in treating cancer by significantly increasing the brain levels of the drugs of the invention and their active metabolites.